Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
159.90
0.00 (0.00%)
At close: Jul 2, 2026, 4:00 PM EDT
157.65
-2.25 (-1.41%)
Pre-market: Jul 6, 2026, 8:01 AM EDT
Novartis AG Revenue
Novartis AG had revenue of $13.52B in the quarter ending March 31, 2026, a decrease of -0.70%. This brings the company's revenue in the last twelve months to $56.58B, up 6.31% year-over-year. In the year 2025, Novartis AG had annual revenue of $56.67B with 9.57% growth.
Revenue (ttm)
$56.58B
Revenue Growth
+6.31%
P/S Ratio
5.15
Revenue / Employee
$751,697
Employees
75,267
Market Cap
291.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56.67B | 4.95B | 9.57% |
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
| Dec 31, 2018 | 46.10B | 2.70B | 6.21% |
| Dec 31, 2017 | 43.40B | -6.03B | -12.20% |
| Dec 31, 2016 | 49.44B | -951.00M | -1.89% |
| Dec 31, 2015 | 50.39B | -3.25B | -6.05% |
| Dec 31, 2014 | 53.63B | 918.00M | 1.74% |
| Dec 31, 2013 | 52.72B | 745.00M | 1.43% |
| Dec 31, 2012 | 51.97B | -7.40B | -12.47% |
| Dec 31, 2011 | 59.38B | 7.81B | 15.15% |
| Dec 31, 2010 | 51.56B | 6.46B | 14.32% |
| Dec 31, 2009 | 45.10B | 2.52B | 5.92% |
| Dec 31, 2008 | 42.58B | 3.64B | 9.34% |
| Dec 31, 2007 | 38.95B | 3.84B | 10.94% |
| Dec 31, 2006 | 35.11B | 5.35B | 17.99% |
| Dec 31, 2005 | 29.75B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 96.36B |
| Merck & Co. | 65.77B |
| Pfizer | 63.32B |
| AbbVie | 62.82B |
| AstraZeneca | 60.44B |
| Sanofi | 54.60B |
| Novo Nordisk | 50.57B |
| Bristol-Myers Squibb Company | 48.48B |
NVS News
- 1 hour ago - Novartis to Acquire Myricx Bio for $1.5B to Boost Cancer Drugs; NVS Stock Falls - TipRanks
- 2 hours ago - Novartis agrees to acquire Myricx Bio for up to $1.5B - TheFly
- 2 hours ago - Novartis to acquire Myricx Bio for $1.1B upfront - TheFly
- 6 hours ago - Novartis to Buy Myricx Bio for Up to $1.5 Billion - WSJ
- 6 hours ago - Novartis to acquire UK-based Myricx Bio for up to $1.5 billion - Reuters
- 4 days ago - Novartis receives EC approval for Itvisma for spinal muscular atrophy - TheFly
- 4 days ago - 3 European Stocks to Carry Investors Through the Back Half of 2026 - MarketBeat
- 12 days ago - Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis - Reuters